# Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

> **NCT05745233** · NA · ENROLLING_BY_INVITATION · sponsor: **China Medical University Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Malignant Ascites

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05745233
- **Lead sponsor:** China Medical University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2021-01-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05745233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05745233, "Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05745233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*